Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04831801 · ClinicalTrials.gov registry record
OAB and the Microbiome
A clinical trial, sponsored by University of Miami.
- Terminated
- Registry status
- 39
- Enrollment target
NCT04831801: Clinical Trial study, sponsored by University of Miami.
NCT04831801 is a clinical trial that was terminated before completion, run by University of Miami. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04831801 was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- 39 participants
- Enrollment target
Study Summary
To determine differences in the urinary microbiomes, identified by polymerase change reaction (PCR) (UTIP™), of female patients with urgency and frequency syndrome with or without pelvic pain (Group A) compared to female controls without symptoms of lower urinary tract symptoms (LUTS) (Group B).
Primary Outcome
Evaluation of urine and perineal samples by PCR.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2023-11-20 |
Why NCT04831801 stopped before completion
NCT04831801 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04831801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04831801 about?
NCT04831801 is a clinical study titled "OAB and the Microbiome". To determine differences in the urinary microbiomes, identified by polymerase change reaction (PCR) (UTIP™), of female patients with urgency and frequency syndrome with or without pelvic pain (Group A) compared to female controls without symptoms of lower urinary tract symptoms (LUTS) (Group B).
What is the current status of trial NCT04831801?
This trial is currently terminated. The enrollment target is 39 participants. The study started on 2021-06-30. Estimated completion is 2023-11-20.
Who is sponsoring clinical trial NCT04831801?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI